Our technology

PLEIOFLOW RF

30%

PERCENTAGE OF PATIENTS DEVELOPING ACUTE RENAL FAILURE POSTOPERATIVELY
(600,000 AKI PATIENTS)

$4-6

BILLION
TOTAL RENAL FAILURE COSTS ASSOCIATED WITH CARDIAC SURGERY

In the course of intra
and post CPB period,

Patients may require support in maintaing adequate oxygenated blood flow, arterial blood pressure and renal perfusion.

Preventing renal failure after heart surgery

Pleioflow-RF is a percutaneous flow assist device of a disruptive, innovative and patented technology, featuring a self-expanding, one way downstream valve, and a pulsating balloon (standard IAB) segment that is, in combination of the latter two, intended to provide temporary circulatory support, during high-risk cardiac surgery, intra and postoperatively.

Pleioflow-RF is introduced percutaneously in the aorta, while on CPB (2-4 hours), either (preferably) via a 9F sheath in the femoral artery, or with a standard Seldinger technique.

Watch it in action

Pleioflow-RF flow assist device is capable of directing the flow of the pumping balloon downstream, towards the periphery and the renal arteries, thus increasing the renal perfusion, and probably preventing renal failure in Cardiac Surgery patients due to renal underperfusion (in clinical trials at present)

Pleioflow-RF device is currently under clinical trials and is not commercially available for any clinical indication. Animated videos of the Pleioflow-RF device may differ from reality, lacking precision

CURRENTLY,

TO OUR KNOWLEDGE, THERE ARE NOT ANY OTHER KNOWN, COST EFFECTIVE METHODS OF PREVENTING RENAL FAILURE IN THESE PATIENTS

PLEIOFLOW HF

There Are More Than
300.000 PATIENTS
IN THE US
That die from heart failure
every year
$21 billion - $53 billion
IS THE PROJECTION OF INCREASE OF DIRECT MEDICAL COSTS
RELATED TO HEART FAILURE
FROM 2012-2030
WORLDWIDE

THE PROBLEM

Other flow assist devices have been used quite widely over the last 40 years, without significant market and clinical inflitration (as low as 1%). A significant number of these, have either been too large/traumatic to be inserted percutaneously, and/or clinically inefficient, and/or not proved sufficiently cost-effective, i.e. they are prohibitely expensive ($10,000+) for the clinical benefit they display.

Augmenting Flow in Heart Failure patients even in cases with very low Cardiac Output

Pleioflow-HF is a minimally invasive blood flow assist device of a disruptive, innovative and patented technology featuring a self-expanding percutaneous catheter-mounted flow assist segment that is intended to provide temporary circulatory support for the left ventricle (LV) during high-risk percutaneous coronary interventions (HR-PCI) and in patients hospitalized with cardiogenic shock (CS) as well as post CPB low cardiac output cases.

In the course of HR-PCI and CS, the LV may require support in pumping oxygenated blood from the ventricle into the aorta, so that adequate cardiac output, arterial blood pressure and coronary and end-organ perfusion can be maintained. In large animal experiments, Pleioflow-HF flow assist device was shown to be able to direct and increase blood flow, both downstream and upstream, and augment the flow even in the upper circulation and the coronary arteries.

In addition, the Pleioflow devices have been shown -in post MI, large animal experiments- to reduce all, the LV end-diastolic pressure, the end-diastolic volume  and the end-systolic volume of the LV, thus decreasing both the myocardial wall stress and overall myocardial oxygen consumption at the same time.

Watch it in action

Pleioflow-HF device is intended for insertion into the patient’s aorta soon after a heart attack. The device will then be introduced in an effort to assist the failing heart to pump blood into the coronary arteries and to the rest of the body, always synchronized with the heartbeat.

Prototype bench tests have shown that the amount of blood pumped by this device is at least four times greater, than the one achieved with one of the other conventional balloon pumps.

Pleioflow-HF device is currently planned for clinical trials and is not commercially available for any clinical indication. Animated videos of the Pleioflow-HF device may differ from reality, lacking precision

WE CHANGE LIVES

Innovative solutions for people fighting CardioVascular Disease

CONTACT US

GET IN TOUCH

Have a question? We are here for you.

    PleioFlow UK LTD.

    74 High Street Swandlincote, Derbyshire,
    United Kingdom DE11 8HS

    info@pleioflow.com

    PleioFlow Hellas SA.

    Peloponnesou 4 & Argolidos 2 Str., 145 64 Kifissia
    Athens, Greece

    +30 210 6209 866

    info@pleioflow.com